The U.S. Food and Drug Administration approved on Tuesday Amgen's Bkemv, the first biosimilar to AstraZeneca's rare blood ...

Amgen’s Bkemv is the first interchangeable biosimilar to Soliris to treat certain rare diseases. The treatment of patients ...

Amgen has made waves in the biosimilar field in recent years with its U.S.-first Humira biosim launch last year and its ...

Amgen on Tuesday secured the FDA’s green light for the first interchangeable biosimilar to AstraZeneca’s Soliris to treat two ...

Uplizna also hit the target on a number of secondary measures, including: annualised flare rate; flare-free, treatment-free ...

Uplizna therapy reaches main goal in Phase 3 trial for IgG4-RD, cutting the risk of flare by 87% with no new safety events.

Amgen Inc. (NASDAQ:AMGN) has recently been in the news due to its involvement in the promising obesity drug market. Analysts ...

The FDA's vaccine advisory panel voted to recommend that this fall’s Covid-19 shots should be updated to target Omicron’s ...

The FDA has made two approvals this week: the first interchangeable biosimilar of Soliris and another indication for Breyanzi ...

Today, the U.S. Food and Drug Administration approved Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to Soliris (eculizumab) to treat certain rare diseases. Bkemv is approved for the ...

ASCO Annual Meeting kicks off today, showcasing the latest research in cancer therapies to scientists and physicians.